Table 3.
Clinical outcomes of postoperative disease status guided RAT.
| Study | Study design | Number | Follow-up period | Tg cut-off (ng/ml) | Endpoint | Prognosis improved yes/no | Dosage | Benefited subgroups |
|---|---|---|---|---|---|---|---|---|
| Richard C Webb et al. (2012) (26) | Meta-analysis | 3947 | 0.6-16y | (Stimulated) 10 | Recurrence | Yes | Na | Ps-Tg ≥10 ng/ml |
| M Brassard et al. (2011) (25) | Retrospective | 715 | Median 6.2y | (Suppressed) 0.27 after 3 months of RAI ablation; (Stimulated) 1.4 after 9-12 months of RAI ablation; | Recurrence | No | 30-100mCi | Na |
| Handkiewicz-Junak et al. (2007) (29) | Retrospective | 235 | 6.8y (0.4y-33.5y) | (Stimulated)30 | Recurrence | Yes | Patients <12y: 2.0-2.5 mCi/kg of body weight; >12y: 60-100mCi |
Ps-Tg ≥30 ng/ml in patients ≤18y |
Here, only current studies with long-term follow-up and large sample sizes are listed.
ps-Tg, postoperative stimulated Tg.